Cannabidiol (Epidiolex) vs Cannabidiol (JZP926)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: cannabinoid · full Epilepsy pipeline
Cannabidiol (Epidiolex)
Marketed by Jazz Pharmaceuticals and partners
NCT02224573 · Phase 3 · completed
This is a genuine open-label extension trial: the title explicitly states 'Open Label Extension Study,' and eligibility required participants to have completed the treatment phase of the prior randomized, double-blind, placebo-controlled core studies (NCT02091206, NCT02091375, NCT02224703, NCT02224560, NCT02224690). It used a single group of 681 participants with no randomization, no blinding, and no comparator arm, so it cannot provide comparative evidence on its own. The primary outcomes were mostly safety measures plus descriptive changes in seizure frequency, and no inferential statistical comparison was conducted.
Next expected readout: August 2027 · NCT05044819 (registry estimate)
Reported efficacy
Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) (met)
Result source: NCT02544763
Cannabidiol (JZP926)
Developed by Jazz Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07723963 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cannabidiol (Epidiolex) | Cannabidiol (JZP926) |
|---|---|---|
| Seizure frequency, % change | -47.3% vs -29.7%−17.6 vs placeboNCT022247034 other results
| —Trial running · NCT07723963 |
| 50% responder rate | —Not posted · NCT02318602 | —Trial running · NCT07723963 |
| Seizure freedom | —Not posted · NCT02318602 | —Trial running · NCT07723963 |
Seizure frequency, % change
- Cannabidiol (Epidiolex)
- -47.3% vs -29.7%−17.6 vs placeboNCT02224703
4 other results
- -41.2% vs -13.7% NCT02224690
- -38.4% vs -18.5% NCT02224560
- -56.4% vs -29.7% NCT02224703
- -36.4% vs -18.5% NCT02224560
- Cannabidiol (JZP926)
- —Trial running · NCT07723963
50% responder rate
- Cannabidiol (Epidiolex)
- —Not posted · NCT02318602
- Cannabidiol (JZP926)
- —Trial running · NCT07723963
Seizure freedom
- Cannabidiol (Epidiolex)
- —Not posted · NCT02318602
- Cannabidiol (JZP926)
- —Trial running · NCT07723963
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cannabidiol (JZP926): no structured comparison results are available for Epilepsy.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cannabidiol (Epidiolex): 4 of 4 rows · Cannabidiol (JZP926): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cannabidiol (Epidiolex) |
|---|---|
| Dropout rate | 46%Dravet Syndromea NCT02224573 · Phase 3 · monotherapy show 20 more results33.6%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · monotherapy 82.3% NCT02544750 · Phase 3 · monotherapy 14.8%20 mg/kg/day NCT02091375 · Phase 3 16.3%20 mg/kg/day NCT02224690 · Phase 3 11.8%20 mg/kg/day NCT02224560 · Phase 3 2.7%10 mg/kg/day NCT02224560 · Phase 3 16.4%50 mg/kg/Day NCT02544763 · Phase 3 13.3%25 mg/kg/Day NCT02544763 · Phase 3 —Cannabidiol OS NCT02954887 · Phase 3 · registry result, not featured evidence 77.8%GWP42003-P OS NCT02954887 · Phase 3 · registry result, not featured evidence 0%Cohort 1: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence 0%Cohort 2: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence 9%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 4.5%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 12.5%20 mg/kg/Day NCT02565108 · Phase 2 · registry result, not featured evidence 11.1%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 12.5%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 0%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 41.3% NCT02700412 · Phase 1 · registry result, not featured evidence 42.7% NCT02695537 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 8.3%Dravet Syndromea NCT02224573 · Phase 3 · monotherapy show 20 more results10.4%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · monotherapy 6.5% NCT02544750 · Phase 3 · monotherapy 13.1%20 mg/kg/day NCT02091375 · Phase 3 9.3%20 mg/kg/day NCT02224690 · Phase 3 5.3%20 mg/kg/day NCT02224560 · Phase 3 1.4%10 mg/kg/day NCT02224560 · Phase 3 11%50 mg/kg/Day NCT02544763 · Phase 3 10.7%25 mg/kg/Day NCT02544763 · Phase 3 —Cannabidiol OS NCT02954887 · Phase 3 · registry result, not featured evidence —GWP42003-P OS NCT02954887 · Phase 3 · registry result, not featured evidence —Cohort 1: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence —Cohort 2: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence 7.5%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 0%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 6.3%20 mg/kg/Day NCT02565108 · Phase 2 · registry result, not featured evidence 0%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 12.5%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 0%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 7.5% NCT02700412 · Phase 1 · registry result, not featured evidence 3.4% NCT02695537 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 42.2%Dravet Syndromea NCT02224573 · Phase 3 · monotherapy show 20 more results42.9%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · monotherapy 24% NCT02544750 · Phase 3 · monotherapy 16.4%20 mg/kg/day NCT02091375 · Phase 3 23.3%20 mg/kg/day NCT02224690 · Phase 3 —20 mg/kg/day NCT02224560 · Phase 3 —10 mg/kg/day NCT02224560 · Phase 3 13.7%50 mg/kg/Day NCT02544763 · Phase 3 21.3%25 mg/kg/Day NCT02544763 · Phase 3 22.2%Cannabidiol OS NCT02954887 · Phase 3 · registry result, not featured evidence —GWP42003-P OS NCT02954887 · Phase 3 · registry result, not featured evidence —Cohort 1: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence —Cohort 2: GWP42003-P OS NCT02953548 · Phase 3 · registry result, not featured evidence 24.6%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 20.3%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 6.3%20 mg/kg/Day NCT02565108 · Phase 2 · registry result, not featured evidence 11.1%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 25%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 10%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 17.5% NCT02700412 · Phase 1 · registry result, not featured evidence 16.9% NCT02695537 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 15 more resultsdiarrhoea 57.3% (placebo 40.3%) decreased appetite 32% (placebo 18.5%) somnolence 32% (placebo 12.1%) NCT02544750 · Phase 3 · monotherapy 20 mg/kg/day diarrhoea 31.1% (placebo 10.2%) somnolence 31.1% (placebo 10.2%) decreased appetite 26.2% (placebo 5.1%) NCT02091375 · Phase 3 20 mg/kg/day diarrhoea 18.6% (placebo 8.2%) somnolence 14% (placebo 9.4%) decreased appetite 12.8% (placebo 2.4%) NCT02224690 · Phase 3 50 mg/kg/Day diarrhoea 54.8% (placebo 25%) somnolence 26% (placebo 9.2%) decreased appetite 23.3% (placebo 11.8%) NCT02544763 · Phase 3 25 mg/kg/Day diarrhoea 30.7% (placebo 25%) decreased appetite 20% (placebo 11.8%) pyrexia 18.7% (placebo 7.9%) NCT02544763 · Phase 3 upper respiratory tract congestion 33.3% anaemia 22.2% blood triglycerides increased 22.2% NCT02954887 · Phase 3 · registry result, not featured evidence 20 mg/kg/Day decreased appetite 27.5% (placebo 16.9%) diarrhoea 26.1% (placebo 12.3%) somnolence 23.2% (placebo 13.8%) NCT02224703 · Phase 3 · registry result, not featured evidence 10 mg/kg/Day pyrexia 23.4% (placebo 16.9%) somnolence 21.9% (placebo 13.8%) diarrhoea 17.2% (placebo 12.3%) NCT02224703 · Phase 3 · registry result, not featured evidence 20 mg/kg/Day diarrhoea 37.5% (placebo 25%) nausea 18.8% (placebo 0%) vomiting 18.8% (placebo 0%) NCT02565108 · Phase 2 · registry result, not featured evidence 20 mg/kg/day decreased appetite 44.4% (placebo 0%) abdominal pain upper 22.2% (placebo 0%) sedation 22.2% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence 10 mg/kg/day somnolence 37.5% (placebo 14.3%) coordination abnormal 12.5% (placebo 0%) decreased appetite 12.5% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence 5 mg/kg/day abnormal behaviour 30% (placebo 0%) pyrexia 30% (placebo 0%) ataxia 20% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence diarrhea 66.3% sedation 18.8% weight loss 17.5% NCT02700412 · Phase 1 · registry result, not featured evidence sedation 43.8% diarrhea 34.8% depression/mood issues 14.6% NCT02695537 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cannabidiol (Epidiolex)
show 3 more results
show 4 more results
show 8 more results
show 1 more result
show 2 more results
show 2 more results
+ 17 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cannabidiol (Epidiolex)'s landscape · Cannabidiol (JZP926)'s landscape